Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Cholangiocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 15Temozolomide 13Specimen Handling 10X-Rays 8Biopsy 7Nuclear Medicine Department, Hospital 6Radiation 5Phantoms, Imaging 5erdafitinib 4ulixertinib 3trametinib 3larotrectinib 3dabrafenib 3Radiotherapy 3tipifarnib 2selpercatinib 2palbociclib 2olaparib 2ivosidenib 2ensartinib 2binimetinib 2Surgical Procedures, Operative 2Nivolumab 2D2C7-(scdsFv)-PE38KDEL 2vorasidenib 1veliparib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1temsirolimus 1tazemetostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × Cytochrome P-450 CYP3A × 30 days × Clear all
NCT07486713 2026-06-05

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡